FindTrial
Sign In

Secondary Cytoreductive Surgery

PROCEDURE6 trials

Sponsors

Shanghai Gynecologic Oncology Group, Memorial Sloan Kettering Cancer Center, Menoufia University, Korea University Guro Hospital, National Cancer Center, Korea

Conditions

Drug Related Neoplasm/CancerFallopian Tube CarcinomaFallopian Tubes CancerOvarian CancerOvarian Cancer RecurrentOvarian Epithelial Cancer RecurrentPeritoneal CancerPlatinum Sensitive Ovarian Cancer

Phase 2

Outcomes After Secondary Cytoreductive Surgery With or Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed by Systemic Combination Chemotherapy for Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
CompletedNCT01767675
Memorial Sloan Kettering Cancer CenterFallopian Tubes Cancer, Ovarian Cancer, Peritoneal Cancer
Start: 2013-01-08End: 2025-08-26Updated: 2025-08-27
Secondary Cytoreductive Surgery in Platinum-resistant Recurrent Ovarian Cancers
WithdrawnNCT04795596
Menoufia UniversityOvarian Cancer, Recurrent Ovarian Carcinoma
Start: 2021-04-01End: 2022-04-09Updated: 2022-04-15
Secondary Cytoreductive Surgery (CRS) in Patients With Relapsed Ovarian Cancer Who Have Progressed on PARP Inhibitor Maintenance
RecruitingNCT05704621
Korea University Guro HospitalDrug Related Neoplasm/Cancer, Ovarian Cancer
Start: 2023-12-01End: 2028-12-28Target: 124Updated: 2025-03-06
Secondary Cytoreductive Surgery After Chemotherapy for Recurrent Epithelial Ovarian Cancer
RecruitingNCT07171528
National Cancer Center, KoreaOvarian Cancer
Start: 2025-09-10End: 2033-12-31Target: 80Updated: 2025-09-12
RESCUE Study (REcurrent Ovarian Cancer Secondary Cytoreduction Using Chemotherapy rEsponse)
Not yet recruitingNCT07295132
Asan Medical CenterOvarian Cancer Recurrent, Platinum Sensitive Ovarian Cancer
Start: 2025-12-15End: 2029-11-15Target: 160Updated: 2025-12-19

Phase 3

Surgery or Chemotherapy in Recurrent Ovarian Cancer (SOC 1 Trial)?
NCT01611766
Shanghai Gynecologic Oncology GroupFallopian Tube Carcinoma, Ovarian Epithelial Cancer Recurrent, Primary Peritoneal Carcinoma
Start: 2012-07-19End: 2022-12-31Target: 356Updated: 2021-06-10

Related Papers

A randomized phase II study of secondary cytoreductive surgery in patients with relapsed ovarian cancer who have progressed on a PARP inhibitor as first-line maintenance therapy: the SOCCER-P study (KGOG 3067/JGOG 3036/APGOT-OV11)
International Journal of Gynecological Cancer2024-08-202 citations
Surgery versus no surgery in platinum-sensitive relapsed ovarian cancer: final overall survival analysis of the SOC-1 randomized phase 3 trial.
2024-06-0117 citations
Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): A final overall survival analysis of a multicenter, open-label, randomized, phase 3 trial.
Journal of Clinical Oncology2024-06-012 citations
Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial.
2021-03-08140 citations
A randomized phase II trial of secondary cytoreductive surgery (SCS) +/- carboplatin hyperthermic intraperitoneal chemotherapy (HIPEC) in patients (pts) with recurrent platinum-sensitive ovarian cancer (EOC).
Journal of Clinical Oncology2020-05-208 citations
A phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum-sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study
Journal of Gynecologic Oncology2020-01-0110 citations